Blue diode laser vaporization for enlarged prostate (BPH)
Blue Diode Laser Vaporization for BPH
It tests whether a 450 nm blue diode laser vaporization can improve urinary symptoms in men aged 50 and older with symptomatic BPH.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 50 Years and up |
| Sex | Male |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT07115147 on ClinicalTrials.gov |
What this trial studies
This is a prospective, single-arm study using a 450 nm blue diode laser to vaporize prostate tissue in men with symptomatic BPH. Each participant is followed for one year with visits at 3, 6, and 12 months after the operation. Clinical follow-up includes blood and urine tests, prostate ultrasound for volume, uroflowmetry, and symptom questionnaires, and all adverse events and unplanned admissions are recorded. The study aims to document safety and clinical outcomes of the blue diode vaporization technique.
Who should consider this trial
Good fit: Men aged 50 years or older with symptomatic benign prostatic hyperplasia who are fit for the procedure and anesthesia are ideal candidates.
Not a fit: Patients with prior TURP, known prostate cancer, urethral stricture, bladder stones, significant neurological bladder dysfunction, active urinary infection, or who cannot undergo anesthesia are unlikely to be eligible or benefit.
Why it matters
Potential benefit: If successful, the procedure could reduce urinary symptoms and improve urine flow using a minimally invasive laser vaporization approach.
How similar studies have performed: Other laser treatments for BPH (for example, green and holmium lasers) have demonstrated good outcomes, but the 450 nm blue diode approach is novel and currently has limited published data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male ≥ 50 years * Symptomatic BPH Exclusion Criteria: * Additional procedure is needed e.g. cystolithotripsy, orchidectomy etc2. Known Ca prostate patients * Patients with history of TURP * Known Urethral stricture / Bladder stone / Hypercontractile bladder * Known neurological diseases which may affect bladder function (e.g. Parkinsonism, stroke) 6. Contraindicated to undergo TURP (e.g. not fit for GA/SA, active urinary tract infection, fail to be placed in lithotomy position, uncorrectable coagulopathy, antiplatelet or anticoagulant which cannot be stopped)
Where this trial is running
Hong Kong
- Prince of Wales Hospital, Chinese University of Hong Kong — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Ka Fung Peter CHIU, MBChB PhD — Chinese University of Hong Kong
- Study coordinator: Ka Fung Peter CHIU, MBChB PhD
- Email: peterchiu@surgery.cuhk.edu.hk
- Phone: 35052625
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.